Breaking News

Trials & Filings in Brief: Oct. 10, 2013

By Gil Roth | October 10, 2013

Alkermes, Chelsea, CirrusGalectin, Gilead, Lundbeck, Otsuka, Medivir, Pergamum and Relyspa

Galectin posts fibrosis . . . read more

Medivir selects neuropathic pain candidate . . . read more

Phase II
Pergamum peptide posts positive results . . . read more

Phase III
Gilead Cuts CLL Study Short After Positive Results  . . . read more

Lundbeck, Otsuka start Alzheimer's trials . . . read more

Relypsa posts positive results for patiromer . . . read more

Alkermes MDD drug gets fast-track status . . . read more

Chelsea NOH treatment to get advisory review . . . read more

Cirrus receives FDA grant for MDI research . . . read more
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials